lifestyle.thedishh.com

Author: Alligator Bioscience

Alligator Bioscience Comments on Henlius Dosing First Patient in Phase 2/3 Breast Cancer Study of HLX22

March 2, 2026
Exercise Price Determined for the Exercise of Warrants Series TO 14 in Alligator Bioscience AB

February 27, 2026
Alligator Bioscience AB Reports Full Year Financial Results for 2025 and for Q4 2025 and Provides a Business Update

February 12, 2026
Invitation to Alligator Bioscience’s Earnings Call on 12 February 2026

February 7, 2026
Change in Number of Shares and Votes in Alligator Bioscience AB

January 30, 2026
Alligator Bioscience to Present New OPTIMIZE-1 Data on Mitazalimab at ASCO Gastrointestinal Cancers Symposium 2026

January 9, 2026
Alligator Bioscience Announces Preliminary Outcome in Rights Issue

December 21, 2025
Alligator Bioscience Comments on Henlius Receiving Regulatory Approval in China to Initiate Phase 2/3 Trials of HLX22 in HER2-Positive Breast Cancer

December 9, 2025